Stabilized trimeric class I fusion proteins patent application

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085096A1) for stabilized trimeric class I fusion proteins. The application details specific mutations in the HR2 domain to enhance protein stability. This is a routine publication of a new patent application.

View original document View source feed page

What changed

This document is a publication of a patent application filed by inventors Johannes Petrus Maria LANGEDIJK, Mark Johannes Gerardus BAKKERS, Annemart KOORNNEEF, and Jaroslaw JURASZEK. The application, titled 'Stabilized trimeric class I fusion proteins,' describes novel fusion proteins with stabilizing mutations in the HR2 domain, potentially impacting the development of new therapeutic proteins.

As this is a patent application publication, there are no immediate compliance obligations for regulated entities. However, companies in the pharmaceutical and biotechnology sectors should monitor this application and related patents for potential future intellectual property considerations and competitive landscape analysis. The application was filed on September 15, 2023, and published on March 26, 2026.

Source document (simplified)

← USPTO Patent Applications

STABILIZED TRIMERIC CLASS I FUSION PROTEINS

Application US20260085096A1 Kind: A1 Mar 26, 2026

Inventors

Johannes Petrus Maria LANGEDIJK, Mark Johannes Gerardus BAKKERS, Annemart KOORNNEEF, Jaroslaw JURASZEK

Abstract

The present invention relates to trimeric class I fusion proteins, in particular to class I fusion proteins, comprising at least one stabilizing mutation in the HR2 domain, and to fragments thereof.